Astellas’s gene therapy aspirations crumble
AT132 has prompted more safety concerns, this time at a lower dose than before.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Jury still out on Sarepta’s next generation
The group’s lead next-gen exon skipper beats a low bar set by Exondys, but adverse events loom large.
Gene therapy data shake Solid
Better-looking safety might not be enough to get Solid back in the Duchenne muscular dystrophy game.
New Nuplazid use in limbo after US knockback
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
